Jo Best
Senior Member
- Messages
- 1,032
Just to add that the UK rituximab research (including the B cell studies) may be best viewed within the context of the Invest in ME Research Centre of Excellence for ME translational biomedical research strategy. The UK researchers are working steadfastly to join the dots in this complex disease in productive collaboration with other researchers in Europe and around the world. At the 2016 Invest in ME Conference, Professor Simon Carding mentioned these areas in his presentation -
I wondered if you'd seen the link about the visit by Dr. Fluge and members of his team to Norwich in January -
http://future.cofeforme.eu/ce-news-1611-02.shtml
In a statement in July 2013 (after he had kindly agreed to advise IiMER on a UK rituximab trial) Professor Jonathan Edwards said -1) Infectious origin
a) environment
b) microbiome alterations
2) Clinical trials
a) Rituximab
b) Bacteria based therapy
I think this has been an important part of the process to date; that these researchers value their own negative findings and use these to proceed to next steps.My interest in ME/CFS was sparked when I was invited, unexpectedly, by IiME to the IiMEC8 Conference in May.
The meeting was impressive: not just professional science, but at a high level. I was particularly impressed that negative findings were given adequate weight. (my bold)
It became clear to me that there was a community committed to identifying and encouraging the very best research in a difficult and neglected field.
I wondered if you'd seen the link about the visit by Dr. Fluge and members of his team to Norwich in January -
http://future.cofeforme.eu/ce-news-1611-02.shtml
Last edited: